Roth Capital Initiates Coverage on Capricor Therapeutics Inc(NASDAQ:CAPR). The shares have been rated Buy. The rating by Roth Capital was issued on Jun 15, 2016.
Capricor Therapeutics Inc (CAPR) shares turned negative on Tuesdays trading session with the shares closing down -0.11 points or -2.48% at a volume of 14,583. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.41. The peak price level was also seen at $4.41 while the days lowest was $4.0601. Finally the shares closed at $4.32. The 52-week high of the shares is $5.48 while the 52-week low is $1.88. According to the latest information available, the market cap of the company is $78 M.
Capricor Therapeutics Inc(CAPR) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.22M. Analysts had an estimated revenue of $1.10M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.19.
Several Insider Transactions has been reported to the SEC. On Mar 21, 2016, Sinai Medical Center Cedars (10% owner) purchased 416,666 shares at $2.40 per share price.Also, On Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price.On Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price, according to the Form-4 filing with the securities and exchange commission.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).